Perrigo Company plc (0Y5E.L)
USD 25.07
(-1.22%)
USD 25.07
(-1.22%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 1.52 Billion USD | 4.67% |
| 2022 | 1.33 Billion USD | 63.52% |
| 2021 | 815.8 Million USD | -39.55% |
| 2020 | 1.34 Billion USD | -0.6% |
| 2019 | 1.35 Billion USD | 0.6% |
| 2018 | 1.34 Billion USD | 6.03% |
| 2017 | 1.27 Billion USD | -8.4% |
| 2016 | 1.38 Billion USD | 44.8% |
| 2015 | 959.6 Million USD | 15.94% |
| 2014 | 827.7 Million USD | 40.53% |
| 2013 | 589 Million USD | 13.79% |
| 2012 | 517.61 Million USD | 25.84% |
| 2011 | 411.32 Million USD | 7.79% |
| 2010 | 381.59 Million USD | 14.33% |
| 2009 | 333.76 Million USD | -4.2% |
| 2008 | 348.38 Million USD | 18.52% |
| 2007 | 293.94 Million USD | 5.9% |
| 2006 | 277.56 Million USD | 40.41% |
| 2005 | 197.68 Million USD | 19.76% |
| 2004 | 165.06 Million USD | 14.05% |
| 2003 | 144.73 Million USD | 22.9% |
| 2002 | 117.76 Million USD | 10.06% |
| 2001 | 107 Million USD | -26.79% |
| 2000 | 146.16 Million USD | -22.58% |
| 1999 | 188.8 Million USD | -41.55% |
| 1998 | 323 Million USD | 74.22% |
| 1997 | 185.4 Million USD | 14.23% |
| 1996 | 162.3 Million USD | 11.93% |
| 1995 | 145 Million USD | 17.89% |
| 1994 | 123 Million USD | 14.74% |
| 1993 | 107.2 Million USD | 38.68% |
| 1992 | 77.3 Million USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 334.6 Million USD | -0.54% |
| 2024 Q2 | 330.2 Million USD | -1.32% |
| 2023 Q4 | 336.4 Million USD | 0.84% |
| 2023 Q2 | 364.5 Million USD | 0.72% |
| 2023 Q1 | 361.9 Million USD | 6.04% |
| 2023 FY | 1.39 Billion USD | 4.67% |
| 2023 Q3 | 333.6 Million USD | -8.48% |
| 2022 Q1 | 312.5 Million USD | 4.31% |
| 2022 FY | 1.33 Billion USD | 63.52% |
| 2022 Q3 | 310.7 Million USD | -15.91% |
| 2022 Q4 | 341.3 Million USD | 9.85% |
| 2022 Q2 | 369.5 Million USD | 18.24% |
| 2021 Q3 | -106.4 Million USD | -134.62% |
| 2021 FY | 815.8 Million USD | -39.55% |
| 2021 Q1 | 315.3 Million USD | -16.01% |
| 2021 Q2 | 307.3 Million USD | -2.54% |
| 2021 Q4 | 299.6 Million USD | 381.58% |
| 2020 Q1 | 337.5 Million USD | -2.6% |
| 2020 Q4 | 375.4 Million USD | 17.17% |
| 2020 Q3 | 320.4 Million USD | 1.33% |
| 2020 FY | 1.34 Billion USD | -0.6% |
| 2020 Q2 | 316.2 Million USD | -6.31% |
| 2019 FY | 1.35 Billion USD | 0.6% |
| 2019 Q3 | 342.3 Million USD | 1.94% |
| 2019 Q4 | 346.5 Million USD | 1.23% |
| 2019 Q1 | 333.1 Million USD | -1.1% |
| 2019 Q2 | 335.8 Million USD | 0.81% |
| 2018 Q4 | 336.8 Million USD | 9.71% |
| 2018 FY | 1.34 Billion USD | 6.03% |
| 2018 Q2 | 370.9 Million USD | 10.75% |
| 2018 Q1 | 334.9 Million USD | -3.71% |
| 2018 Q3 | 307 Million USD | -17.23% |
| 2017 Q1 | 285 Million USD | -20.26% |
| 2017 Q2 | 316.3 Million USD | 10.98% |
| 2017 Q3 | 323.8 Million USD | 2.37% |
| 2017 Q4 | 347.8 Million USD | 7.41% |
| 2017 FY | 1.27 Billion USD | -8.4% |
| 2016 Q4 | 357.4 Million USD | 6.69% |
| 2016 FY | 1.38 Billion USD | 44.8% |
| 2016 Q2 | 342.9 Million USD | -3.22% |
| 2016 Q1 | 354.3 Million USD | -14.23% |
| 2016 Q3 | 335 Million USD | -2.3% |
| 2015 Q1 | 178.5 Million USD | -9.39% |
| 2015 Q4 | 413.1 Million USD | 15.39% |
| 2015 FY | 959.6 Million USD | 15.94% |
| 2015 Q2 | 401.3 Million USD | 124.82% |
| 2015 Q3 | 358 Million USD | -10.79% |
| 2014 Q3 | 182.9 Million USD | -11.98% |
| 2014 FY | 827.7 Million USD | 40.53% |
| 2014 Q1 | 192.2 Million USD | -24.09% |
| 2014 Q2 | 207.8 Million USD | 8.12% |
| 2014 Q4 | 197 Million USD | 7.71% |
| 2013 Q3 | 174.5 Million USD | 6.25% |
| 2013 Q4 | 253.2 Million USD | 45.1% |
| 2013 Q1 | 152.75 Million USD | 6.59% |
| 2013 FY | 589 Million USD | 13.79% |
| 2013 Q2 | 164.24 Million USD | 7.52% |
| 2012 FY | 517.61 Million USD | 25.84% |
| 2012 Q3 | 128.69 Million USD | -1.95% |
| 2012 Q2 | 131.26 Million USD | 4.07% |
| 2012 Q1 | 126.12 Million USD | -6.02% |
| 2012 Q4 | 143.3 Million USD | 11.35% |
| 2011 Q1 | 105.25 Million USD | -10.24% |
| 2011 FY | 411.32 Million USD | 7.79% |
| 2011 Q4 | 134.2 Million USD | 6.49% |
| 2011 Q3 | 126.02 Million USD | 17.32% |
| 2011 Q2 | 107.42 Million USD | 2.06% |
| 2010 Q3 | 102.18 Million USD | -10.84% |
| 2010 Q4 | 117.26 Million USD | 14.75% |
| 2010 Q1 | 91.08 Million USD | -7.51% |
| 2010 Q2 | 114.61 Million USD | 25.83% |
| 2010 FY | 381.59 Million USD | 14.33% |
| 2009 Q1 | 77.69 Million USD | -16.77% |
| 2009 Q3 | 77.42 Million USD | -17.35% |
| 2009 Q4 | 98.47 Million USD | 27.19% |
| 2009 FY | 333.76 Million USD | -4.2% |
| 2009 Q2 | 93.68 Million USD | 20.58% |
| 2008 Q4 | 93.35 Million USD | 9.14% |
| 2008 Q1 | 59.68 Million USD | -26.83% |
| 2008 Q2 | 101.13 Million USD | 69.44% |
| 2008 Q3 | 85.53 Million USD | -15.42% |
| 2008 FY | 348.38 Million USD | 18.52% |
| 2007 Q4 | 81.57 Million USD | 15.43% |
| 2007 FY | 293.94 Million USD | 5.9% |
| 2007 Q1 | 68.12 Million USD | -4.45% |
| 2007 Q3 | 70.66 Million USD | -17.46% |
| 2007 Q2 | 85.62 Million USD | 25.69% |
| 2006 FY | 277.56 Million USD | 40.41% |
| 2006 Q4 | 71.29 Million USD | 3.47% |
| 2006 Q3 | 68.9 Million USD | -11.88% |
| 2006 Q2 | 78.19 Million USD | 16.84% |
| 2006 Q1 | 66.92 Million USD | 1.0% |
| 2005 Q2 | -315.72 Million USD | -173.01% |
| 2005 FY | 197.68 Million USD | 19.76% |
| 2005 Q4 | 66.26 Million USD | 0.11% |
| 2005 Q3 | 66.18 Million USD | 120.96% |
| 2005 Q1 | 432.4 Million USD | 907.78% |
| 2004 Q2 | 57.18 Million USD | 42.52% |
| 2004 Q1 | 40.12 Million USD | 14.22% |
| 2004 FY | 165.06 Million USD | 14.05% |
| 2004 Q4 | 42.9 Million USD | 12.66% |
| 2004 Q3 | 38.08 Million USD | -33.39% |
| 2003 Q1 | 36.18 Million USD | -4.66% |
| 2003 Q4 | 35.12 Million USD | 7.61% |
| 2003 Q2 | 38.65 Million USD | 6.83% |
| 2003 Q3 | 32.64 Million USD | -15.55% |
| 2003 FY | 144.73 Million USD | 22.9% |
| 2002 Q3 | 30.61 Million USD | 7.07% |
| 2002 Q1 | 25.29 Million USD | -24.35% |
| 2002 FY | 117.76 Million USD | 10.06% |
| 2002 Q4 | 37.95 Million USD | 23.95% |
| 2002 Q2 | 28.59 Million USD | 13.05% |
| 2001 Q4 | 33.43 Million USD | 9.86% |
| 2001 Q1 | 33.15 Million USD | -10.87% |
| 2001 FY | 107 Million USD | -26.79% |
| 2001 Q2 | 12.19 Million USD | -63.21% |
| 2001 Q3 | 30.43 Million USD | 149.58% |
| 2000 Q1 | 26.8 Million USD | -23.62% |
| 2000 FY | 146.16 Million USD | -22.58% |
| 2000 Q3 | 36.68 Million USD | -9.57% |
| 2000 Q2 | 40.56 Million USD | 51.31% |
| 2000 Q4 | 37.19 Million USD | 1.41% |
| 1999 Q3 | 37.8 Million USD | -15.06% |
| 1999 FY | 188.8 Million USD | -41.55% |
| 1999 Q1 | 43.4 Million USD | -7.26% |
| 1999 Q2 | 44.5 Million USD | 2.53% |
| 1999 Q4 | 35.1 Million USD | -7.14% |
| 1998 Q4 | 46.8 Million USD | -13.33% |
| 1998 FY | 323 Million USD | 74.22% |
| 1998 Q2 | 185.2 Million USD | 300.87% |
| 1998 Q1 | 46.2 Million USD | -4.15% |
| 1998 Q3 | 54 Million USD | -70.84% |
| 1997 FY | 185.4 Million USD | 14.23% |
| 1997 Q3 | 44 Million USD | -4.35% |
| 1997 Q2 | 46 Million USD | -1.29% |
| 1997 Q1 | 46.6 Million USD | -2.51% |
| 1997 Q4 | 48.2 Million USD | 9.55% |
| 1996 Q3 | 43.1 Million USD | -36.05% |
| 1996 Q2 | 67.4 Million USD | 75.52% |
| 1996 Q1 | 38.4 Million USD | 0.26% |
| 1996 FY | 162.3 Million USD | 11.93% |
| 1996 Q4 | 47.8 Million USD | 10.9% |
| 1995 FY | 145 Million USD | 17.89% |
| 1995 Q3 | 38.3 Million USD | -5.43% |
| 1995 Q2 | 40.5 Million USD | 16.38% |
| 1995 Q4 | 38.3 Million USD | 0.0% |
| 1995 Q1 | 34.8 Million USD | 3.26% |
| 1994 Q4 | 33.7 Million USD | -5.07% |
| 1994 FY | 123 Million USD | 14.74% |
| 1994 Q3 | 35.5 Million USD | 15.64% |
| 1994 Q1 | 31.3 Million USD | 3.3% |
| 1994 Q2 | 30.7 Million USD | -1.92% |
| 1993 FY | 107.2 Million USD | 38.68% |
| 1993 Q1 | 26.5 Million USD | 4.33% |
| 1993 Q2 | 27.6 Million USD | 4.15% |
| 1993 Q3 | 30.5 Million USD | 10.51% |
| 1993 Q4 | 30.3 Million USD | -0.66% |
| 1992 Q4 | 25.4 Million USD | -8.63% |
| 1992 Q1 | 22.2 Million USD | 37.89% |
| 1992 Q2 | 22.9 Million USD | 3.15% |
| 1992 Q3 | 27.8 Million USD | 21.4% |
| 1992 FY | 77.3 Million USD | 0.0% |
| 1991 Q4 | 16.1 Million USD | 0.0% |
| 1991 Q3 | - USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Imunon, Inc. | 21.03 Million USD | -7168.04% |
| Homology Medicines, Inc. | 9.87 Million USD | -15378.481% |
| uniQure N.V. | 285.08 Million USD | -436.154% |
| Abeona Therapeutics Inc. | 48.5 Million USD | -3051.416% |
| Aclaris Therapeutics, Inc. | 12.14 Million USD | -12489.573% |
| Agios Pharmaceuticals, Inc. | 408.8 Million USD | -273.894% |
| Amicus Therapeutics, Inc. | 427.65 Million USD | -257.418% |
| Atara Biotherapeutics, Inc. | 275.69 Million USD | -454.421% |
| bluebird bio, Inc. | 240.23 Million USD | -536.26% |
| Blueprint Medicines Corporation | 722.86 Million USD | -111.451% |
| Cara Therapeutics, Inc. | 142.46 Million USD | -972.91% |
| Adicet Bio, Inc. | 152.03 Million USD | -905.341% |
| Dynavax Technologies Corporation | 219.14 Million USD | -597.483% |
| Editas Medicine, Inc. | 247.3 Million USD | -518.065% |
| Esperion Therapeutics, Inc. | 271.89 Million USD | -462.161% |
| Geron Corporation | 70.44 Million USD | -2069.901% |
| Heron Therapeutics, Inc. | 120.65 Million USD | -1166.814% |
| Illumina, Inc. | 3.81 Billion USD | 59.913% |
| Iovance Biotherapeutics, Inc. | 450.99 Million USD | -238.919% |
| IQVIA Holdings Inc. | 2.05 Billion USD | 25.548% |
| Mettler-Toledo International Inc. | 1.08 Billion USD | -40.308% |
| Myriad Genetics, Inc. | 600.1 Million USD | -154.708% |
| Neurocrine Biosciences, Inc. | 1.59 Billion USD | 4.259% |
| Sarepta Therapeutics, Inc. | 1.36 Billion USD | -12.322% |
| Supernus Pharmaceuticals, Inc. | 529.01 Million USD | -188.935% |
| Verastem, Inc. | 92.08 Million USD | -1559.897% |
| Walgreens Boots Alliance, Inc. | 40.6 Billion USD | 96.235% |
| Waters Corporation | 943.51 Million USD | -62.0% |
| Vertex Pharmaceuticals Incorporated | 4.77 Billion USD | 67.99% |
| Thermo Fisher Scientific Inc. | 10.25 Billion USD | 85.094% |
| Biogen Inc. | 5.2 Billion USD | 70.633% |
| Nektar Therapeutics | 190.9 Million USD | -700.668% |
| Viking Therapeutics, Inc. | 100.82 Million USD | -1415.963% |
| Unity Biotechnology, Inc. | 44.66 Million USD | -3321.989% |
| Corbus Pharmaceuticals Holdings, Inc. | 13.9 Million USD | -10888.781% |
| BioMarin Pharmaceutical Inc. | 1.74 Billion USD | 12.471% |
| Sangamo Therapeutics, Inc. | 228.68 Million USD | -568.401% |
| Evolus, Inc. | 189.75 Million USD | -705.495% |
| Regeneron Pharmaceuticals, Inc. | 2.81 Billion USD | 45.707% |
| FibroGen, Inc. | 398.11 Million USD | -283.936% |
| Agilent Technologies, Inc. | 2.11 Billion USD | 27.73% |
| OPKO Health, Inc. | 574.68 Million USD | -165.971% |
| Alnylam Pharmaceuticals, Inc. | 1.8 Billion USD | 15.086% |
| Exelixis, Inc. | 1.58 Billion USD | 3.673% |
| Anavex Life Sciences Corp. | 55.75 Million USD | -2641.409% |
| Intellia Therapeutics, Inc. | 551.56 Million USD | -177.12% |
| Zoetis Inc. | 2.76 Billion USD | 44.72% |
| Axsome Therapeutics, Inc. | 476.36 Million USD | -220.871% |
| Kala Pharmaceuticals, Inc. | 39.15 Million USD | -3803.915% |
| Ionis Pharmaceuticals, Inc. | 779.58 Million USD | -96.065% |
| Corcept Therapeutics Incorporated | 368.61 Million USD | -314.664% |
| Halozyme Therapeutics, Inc. | 299.31 Million USD | -410.661% |
| Insmed Incorporated | 949.26 Million USD | -61.02% |
| TG Therapeutics, Inc. | 198.47 Million USD | -670.122% |
| Incyte Corporation | 1.19 Billion USD | -28.392% |
| Emergent BioSolutions Inc. | 1.04 Billion USD | -46.408% |